Literature DB >> 6421793

Activity of imipenem on aerobic bacteria.

J F Acar, F W Goldstein, M D Kitzis, L Gutmann.   

Abstract

Imipenem is a new carbapenem antibiotic with a broad spectrum of activity on Gram-positive and Gram-negative bacteria. It is a potent inhibitor of plasmid- and chromosomally-mediated beta-lactamases. The purpose of this study was to evaluate the in vitro activity of imipenem on clinical isolates classified according to their susceptibility to beta-lactam antibiotics. On penicillin G-susceptible bacteria, imipenem is comparable to penicillin. On streptococci, pneumococci, Staphylococcus aureus and Listeria the MICs were 0.02 to 0.06 mg/l. On gonococci, MICs were 0.04 to 0.25 mg/l. Gram-negative bacteria susceptible to beta-lactam antibiotics or naturally resistant to certain of them (e.g. Klebsiella pneumoniae resistant to ampicillin and carbenicillin) were highly susceptible to imipenem with MICs from 0.06 to 0.5 mg/l. It was slightly less active on Haemophilus influenzae, compared to ampicillin. On beta-lactam-resistant bacteria, imipenem maintained a remarkable activity. For penicillin-resistant pneumococci (MIC 16 mg/l) the imipenem MIC was 1 mg/l. Imipenem was equally effective on beta-lactamase-producing and non-producing Haemophilus influenzae and gonococci. Among 12 Nocardia asteroides tested, 11 had MIC less than 1 mg/l. When tested at 30 degrees, the MIC of imipenem for oxacillin-resistant Staphylococcus aureus ranged from 8 to 64 mg/l in contrast to 0.03 to 0.06 mg/l for oxacillin-sensitive isolates. Eighteen strains of enterococci (17 faecium, 2 faecalis) resistant to ampicillin (MIC 128 mg/l) were more resistant to imipenem (MIC 16 to 256 mg/l). Imipenem was very active on beta-lactam-resistant Gram-negative bacteria, including multiply-resistant Salmonella typhi., with MICs in a range from 0.06 to 4 mg/l).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6421793     DOI: 10.1093/jac/12.suppl_d.37

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 2.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 3.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

4.  Pharmacokinetics of imipenem-cilastatin in neonates.

Authors:  B J Freij; G H McCracken; K D Olsen; N Threlkeld
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.

Authors:  W Fan; R del Busto; M Love; N Markowitz; C Cendrowski; J Cardenas; E Quinn; L Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.